Dr. Chesworth is an entrepreneur in residence at Third Rock Ventures, focused on building new drug discovery and development companies. He has contributed to the research and development of thirteen different compounds entering clinical trials, resulting in two FDA-approved new molecular entities, including TAZVERIK® for the treatment of both epithelioid sarcoma and relapsed/refractory follicular lymphoma. Dr. Chesworth previously served as chief scientific officer at Kymera Therapeutics, head of chemistry and senior vice president of research at Epizyme, head of chemistry at EnVivo, and principal scientist at Surface Logix and Pfizer. Dr. Chesworth holds a BSc in Chemistry from Imperial College of Science, Technology and Medicine at the University of London and a D.Phil. in Chemistry from the University of Oxford.
About
